- Home
- NSPR vs ALXO Comparison
NSPR vs ALXO Comparison
Compare NSPR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSPR
- ALXO
- Stock Information
- Founded
- NSPR 2005
- ALXO 2015
- Country
- NSPR United States
- ALXO United States
- Employees
- NSPR N/A
- ALXO N/A
- Industry
- NSPR Medical/Dental Instruments
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- NSPR Health Care
- ALXO Health Care
- Exchange
- NSPR Nasdaq
- ALXO Nasdaq
- Market Cap
- NSPR 75.6M
- ALXO 76.5M
- IPO Year
- NSPR N/A
- ALXO 2020
- Fundamental
- Price
- NSPR $2.61
- ALXO $0.60
- Analyst Decision
- NSPR Strong Buy
- ALXO Strong Buy
- Analyst Count
- NSPR 2
- ALXO 6
- Target Price
- NSPR $4.75
- ALXO $4.14
- AVG Volume (30 Days)
- NSPR 64.7K
- ALXO 1.4M
- Earning Date
- NSPR 05-13-2025
- ALXO 03-06-2025
- Dividend Yield
- NSPR N/A
- ALXO N/A
- EPS Growth
- NSPR N/A
- ALXO N/A
- EPS
- NSPR N/A
- ALXO N/A
- Revenue
- NSPR $7,009,000.00
- ALXO N/A
- Revenue This Year
- NSPR $28.93
- ALXO N/A
- Revenue Next Year
- NSPR $172.18
- ALXO N/A
- P/E Ratio
- NSPR N/A
- ALXO N/A
- Revenue Growth
- NSPR 12.96
- ALXO N/A
- 52 Week Low
- NSPR $1.81
- ALXO $0.57
- 52 Week High
- NSPR $3.80
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- NSPR 38.11
- ALXO 30.55
- Support Level
- NSPR $2.57
- ALXO $0.59
- Resistance Level
- NSPR $2.71
- ALXO $0.72
- Average True Range (ATR)
- NSPR 0.17
- ALXO 0.06
- MACD
- NSPR -0.02
- ALXO -0.00
- Stochastic Oscillator
- NSPR 24.00
- ALXO 8.19
Stock Price Comparison Chart: NSPR vs ALXO
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.